Seelos Therapeutics is a biopharmaceutical company that specializes in creating treatments for a variety of disorders, including central nervous system and respiratory disorders. The company is currently in the clinical stage of developing three lead programs - intranasal racemic ketamine for depression, protein stabilizer for lateral sclerosis and Sanfilippo syndrome, and a partial dopamine agonist for Parkinson's disease. Seelos Therapeutics's preclinical programs include an anti-alpha-synuclein peptidic inhibitor, an orally available antagonist for chronic inflammation in asthma, an oral histamine H3A receptor antagonist, and an injectable therapy for post-operative pain management.